Generate Biomedicines (NASDAQ:GENB) Raised to “Hold” at Wall Street Zen

Generate Biomedicines (NASDAQ:GENB) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Saturday.

A number of other brokerages have also recently issued reports on GENB. HC Wainwright lifted their price objective on shares of Generate Biomedicines from $16.00 to $25.00 and gave the company a “buy” rating in a report on Friday, May 8th. Morgan Stanley upped their target price on shares of Generate Biomedicines from $20.00 to $22.00 and gave the stock an “overweight” rating in a report on Thursday, May 14th. Six investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, Generate Biomedicines presently has an average rating of “Moderate Buy” and a consensus price target of $25.40.

Generate Biomedicines Stock Performance

Shares of GENB opened at $13.40 on Friday. The stock has a fifty day moving average price of $14.34. Generate Biomedicines has a 12-month low of $11.00 and a 12-month high of $18.18. The company has a market cap of $1.72 billion and a PE ratio of -12.52.

Generate Biomedicines (NASDAQ:GENB) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($1.07) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.59).

About Generate Biomedicines

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.